Senti Biosciences (NASDAQ:SNTI) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Senti Biosciences (NASDAQ:SNTI) announced its quarterly earnings data on Friday. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08), FiscalAI reports. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million.

Senti Biosciences Trading Up 16.9%

NASDAQ:SNTI traded up $0.07 during trading hours on Friday, hitting $0.45. The company had a trading volume of 603,575 shares, compared to its average volume of 218,567. Senti Biosciences has a 1 year low of $0.33 and a 1 year high of $2.88. The company has a market cap of $13.99 million, a P/E ratio of -0.23 and a beta of 2.10. The company has a 50-day moving average of $0.74 and a 200 day moving average of $0.87.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC increased its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Armistice Capital LLC acquired a new position in Senti Biosciences in the 2nd quarter valued at about $1,883,000. Citadel Advisors LLC purchased a new stake in shares of Senti Biosciences in the 3rd quarter valued at approximately $117,000. Jane Street Group LLC purchased a new stake in shares of Senti Biosciences in the 4th quarter valued at approximately $40,000. Finally, Virtu Financial LLC acquired a new stake in shares of Senti Biosciences during the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Analysts Set New Price Targets

SNTI has been the topic of several research reports. Chardan Capital raised their price target on shares of Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.